| Institution: | 1. Department of Pulmonology, Kameda Medical Center. Kamogawa, Chiba, Japan;2. Department of Public Health, Osaka City University Graduate School of Medicine, Osaka, Japan;3. Nagoya City University, School of Nursing, Nagoya, Japan;4. Department of Community-based Medical Education, Nagoya City Graduate School of Medical Sciences, Nagoya, Japan;5. Child Health Nursing, Course of Nursing Science, Graduate School of Medicine, Mie University, Tsu, Mie, Japan;6. Research Center for Infectious Disease Sciences, Osaka City University Graduate School of Medicine, Osaka, Japan;7. Clinical Epidemiology Research Center, Medical Co. LTA, Fukuoka, Japan;8. Management bureau, Osaka City University Hospital, Osaka, Japan;1. Department of Pulmonology, Kameda Medical Center. Kamogawa, Chiba, Japan;2. Department of Public Health, Osaka City University Graduate School of Medicine, Osaka, Japan;3. Nagoya City University, School of Nursing, Nagoya, Japan;4. Department of Community-based Medical Education, Nagoya City Graduate School of Medical Sciences, Nagoya, Japan;5. Child Health Nursing, Course of Nursing Science, Graduate School of Medicine, Mie University, Tsu, Mie, Japan;6. Research Center for Infectious Disease Sciences, Osaka City University Graduate School of Medicine, Osaka, Japan;7. Clinical Epidemiology Research Center, Medical Co. LTA, Fukuoka, Japan;8. Management bureau, Osaka City University Hospital, Osaka, Japan |
| Abstract: | BackgroundIn the era of childhood pneumococcal conjugate vaccine (PCV) immunization, especially 13-valent pneumococcal conjugate vaccine (PCV13) immunization, serotype replacement of Streptococcus pneumoniae and herd immunity in adults have been reported worldwide. Therefore, continuous evaluation of the effectiveness of the pneumococcal vaccine in adults is crucial because vaccine effectiveness may change owing to these factors. The purpose of this study was to evaluate the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) against all-cause pneumonia and pneumococcal pneumonia in older individuals with community-acquired pneumonia (CAP) after the introduction of childhood PCV13 in Japan, a topic that has remained largely unexplored.MethodsWe evaluated pneumococcal vaccine effectiveness in this multicenter, matched case-control study conducted in hospitals and clinics. Cases included patients (aged ≥ 65 years) newly diagnosed with CAP between October 2016 and September 2019. A maximum of five non-pneumonia control patients matched for sex, school grade, date of outpatient visit, and medical institution were selected for each case. Conditional logistic regression models were used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) of pneumococcal vaccines for the occurrence of all-cause CAP and pneumococcal CAP.ResultsThe analysis included 740 individuals (142 patients and 598 controls). The median age of participants was 75 years (men: 54%). The adjusted OR for pneumococcal vaccination against all-cause CAP was 1.31 (95% CI: 0.84–2.06), while that for PPSV23 vaccination in the previous 5 years was 1.33 (95% CI: 0.85–2.09). The adjusted OR for PPSV23 vaccination in the previous 5 years against pneumococcal CAP was 0.93 (95% CI: 0.35–2.50).ConclusionsThis study was unable to demonstrate the effectiveness of PPSV23 against all-cause and pneumococcal pneumonia after the introduction of childhood PCV13 in Japan. Nonetheless, additional studies are needed to validate these results. |
